Repligen | RGEN - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Agilent USD 1.81B 49M 2026-03
Align Technology USD 1.06B 35.07M 2026-03
Bio Techne USD 209.82M 36.94M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Bruker USD 133.4M 165.4M 2026-03
Charles River Laboratories USD 191.83M 21.94M 2026-03
Danaher USD 5.7B 1.09B 2026-03
Dentsply International USD 190M 136M 2026-03
General Electric Aerospace USD 10.98B 1.41B 2026-03
Henry Schein USD 138M 18M 2026-03
Illumina USD 1.42B 368M 2025-12
IQVIA Holdings USD 1.95B 33M 2026-03
Mettler Toledo International USD 66.89M 2.18M 2025-12
Myriad Genetics USD 124.4M 25.2M 2026-03
OraSure Technologies USD 176.96M 22.31M 2026-03
Pacific Biosciences Of California USD 56.27M 223.23M 2026-03
Pfizer USD 1.7B 561M 2026-03
Repligen USD 582.65M 16.63M 2026-03
Revvity USD 860.32M 59.54M 2026-03
Standard Biotools USD 265.77M 147.56M 2026-03
Thermo Fisher Scientific USD 3.25B 6.6B 2026-03
Waters USD 462M 125.83M 2026-03
West Pharmaceutical Services USD 521.4M 269.9M 2026-03